The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
ABBVIE INC | Common | 00287Y109 | 721,672 | 11,656,800 | SH | SOLE | 11,394,500 | 0 | 262,300 | ||
ALKERMES PLC | SHS | G01767105 | 325,686 | 7,535,533 | SH | SOLE | 7,353,733 | 0 | 181,800 | ||
NORTHWEST BIOTHERAPEUTICS INC | Common | 66737P600 | 15,065 | 25,915,937 | SH | SOLE | 24,815,028 | 0 | 1,100,909 | ||
PROTHENA CORP PLC | SHS | G72800108 | 360,254 | 10,304,751 | SH | SOLE | 9,934,090 | 0 | 370,661 | ||
REYNOLDS AMERICAN INC | Common | 761713106 | 502,760 | 9,322,463 | SH | SOLE | 9,072,345 | 0 | 250,118 | ||
THERAVANCE BIOPHARMA INC | Common | G8807B106 | 198,166 | 8,733,637 | SH | SOLE | 8,346,146 | 0 | 387,491 | ||
BIOGEN INC | Common | 09062X103 | 4,836 | 20,000 | SH | SOLE | 20,000 | 0 | 0 |